Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Alligator Bioscience AB ( (SE:ATORX) ) has shared an announcement.
Alligator Bioscience presented promising biomarker data from its OPTIMIZE-1 trial at the ASCO 2025 Annual Meeting, showcasing the potential of mitazalimab in treating metastatic pancreatic cancer. The trial demonstrated a significant survival rate and highlighted the drug’s immunological mechanism, supporting its continued development and a planned confirmatory trial, which could enhance Alligator’s position in the oncology market.
More about Alligator Bioscience AB
Alligator Bioscience is a clinical-stage biotechnology company based in Lund, Sweden, specializing in the development of tumor-directed immuno-oncology antibody drugs. The company focuses on the CD40 receptor to enhance tumor-specific T cell priming and counteract the immunosuppressive tumor microenvironment, offering potential benefits for cancer patients across various cancer types. Alligator’s lead drug candidate, mitazalimab, is advancing towards Phase 3 development, having shown promising survival data in metastatic pancreatic cancer.
Average Trading Volume: 240,868
Current Market Cap: SEK130.4M
Learn more about ATORX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue